March 3, 2020 / 1:13 PM / a month ago

BRIEF-Magenta Therapeutics Anticipates That Its Cash, Cash Equivalents Will Be Sufficient To Fund Operations And Capital Expenditures Into Q4 Of 2021

March 3 (Reuters) - Magenta Therapeutics Inc:

* MAGENTA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

* MAGENTA THERAPEUTICS - ANTICIPATES THAT ITS CASH, CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS AND CAPITAL EXPENDITURES INTO Q4 OF 2021

* MAGENTA THERAPEUTICS INC - ADVANCING MGTA-117 TO GENERATE CLINICAL DATA IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below